US FDA Food Nanotechnology Guidelines: Where we are What is next. October 5, 2011
|
|
- Trevor Stewart
- 6 years ago
- Views:
Transcription
1 US FDA Food Nanotechnology Guidelines: Where we are What is next October 5, 2011
2 Overall FDA Approach (to date) Legal authorities apply no worse for nano than they do for other food regulatory categories (food additive, GRAS, dietary supplements) Can ask the right questions where allowed, or infer the same level of protection for industry self assessment No indication that nano-scale in food is more hazardous than non-nano-scale First step: collect data where manufacturing for effect causes size variation in submicron range Specific exposure/toxicity guidance will come with understanding that follows
3 Guidance so far has been 1. When nano-characteristics data are needed Chemistry guidance that does not say nano 2. When FDA is likely to ask nano-specific questions Reviewer s Guidance (Manual of Policies and Procedures) FDA-wide no definition guidance 3. What are the boundaries of new authorization required or come talk to us. Regulatory category specific started with Dietary Supplements
4 Context 2007 FDA Nanotechnology Task Force Report US Government-wide Policy (July 2011 version) EPA Guidance and Rulemaking in Progress
5 2007 FDA Nanotechnology Task Force Report Bottom Lines Nanoscale materials present challenges similar to other emerging technologies The fact that safety and efficacy can vary with size can complicate the challenges Not apparent that nanoscale materials as a group would have more inherent hazard than other materials as a group Need to better inform FDA reviewers and industry about what is known and expected for analysis of nanoscale materials in products. 5
6 The fact that safety and efficacy can vary with size can complicate the challenges Size or particle-surface related impurity What to test in maximum tolerated dose studies to inform low dose risk
7 What to test? The typical nanomaterial is a mixture of distributions Composition Size Aspect ratio %Coating Pb As Hg Se Fe Sb yy xx Surface adherents
8 Transformations will change the distributions that make up the nanomaterial mixture. Neat source material in toxicity study in food container How do we know we are studying the right material distributions in toxicity studies? released to food Released in gut
9 Tracking potency? choose wisely What causes the external dose of a given nanomaterial to be toxic? How do you track it? For example, for benzene, it s the benzene you follow from release to receptor. For a metal oxide nano-object it could be a functional assay, or uncoated surface area, or coated area, or rutile vs anatase crystal fraction, or size for a certain morphology, or something else. anatase rutile TiO 2
10 US Government-wide Context Emerging Technology Policy Coordinating group: existing regulatory statutes provide a firm foundation for the regulation and oversight of nanomaterials; in particular these statutes address a range of potential applications for the technology. Federal agencies should avoid making scientifically unfounded generalizations that categorically judge all applications of nanotechnology as intrinsically benign or harmful. Federal agencies will strive to provide their stakeholders with clear information that delineates the specific risks identified and the context in which they arise.
11 US Environment Protection Agency Issuing a testing rule under new chemicals authority for specific nanomaterials Has developed a size-based rationale for requiring information in pesticide registrations Policy describes agency discretion to include and exclude materials for the nano requirements. For example, Silver and Carbon Nanotubes are in clay and proteins are out
12 US government-wide trend to use submicron feature size as a gateway question, but regulate for specific categories of materials.
13 FDA Guidance in Place Chemistry specifications 2007 Food Contact Notifications 2009 Food Additive Petitions 2009 Color Additive Petitions Routine updates, no public comment period offered, no mention of nano (stealth nano guidance) Requires data if function is related to size
14 The Chemistry Guidance Language 2007 Food Contact Notifications Guidance update Physical/Chemical Specifications. In cases where particle size is important to achieving the technical effect or may relate to toxicity, sponsors should describe particle size, size distribution, and morphology, as well as any size-dependent properties. Intended Chemical Effect. If technical effect is dependent on particle size, sponsors should present data that demonstrate the specific properties of the particles that make them useful for food-contact applications.
15 2009 Direct Food Additive and Color Additive Petitions Guidance updates If the particle size is important for the (color) additive to achieve its intended technical effect, such that the (color) additive is produced or processed using techniques or tools that manipulate the particle size and may contain altered particles that are formed as manufacturing by-products, data on the size (average and distribution), shape, surface area (average and distribution), surface charge (zeta potential), and morphology of the particles, as well as any other sizedependent properties (e.g., agglomeration, aggregation, dispersion) should be included, as appropriate.
16 atoryinformation/ucm htm dancedocuments/foodingredientsandpackaging/ucm htm dancedocuments/foodingredientsandpackaging/ucm htm
17 Data on Size-related Purity 2009 Direct Food Additive Petitions Guidance update (continued) Specifications for Identity and Purity Parameters related to the particle size, shape, and surface properties of the food additive, as appropriate, if particle size is important for the identity and functionality of the additive.
18 What does impurity mean for a nanomaterial when size or shape or surface coating determines properties? size size size 100% within range 50% within range 50% impurity? 10% within range 90% impurity? 18
19 More Data Collection: FDA Reviewer Guidance Center for Drug Evaluation and Research and Center for Veterinary Medicine: Manual of Policies and Procedures Policy for where FDA reviewers should populate an internal FDA database on nanomaterials in products No additional manufacturer reporting requirements The 1 micron upper limit was begun here Internal pressure for Center for Food Safety to adopt similar procedures. nualofpoliciesprocedures/ucm pdf
20 Next Step: Clarify Regulatory Status Boundaries Phase 1: 2011 FDA-wide Guidance (Draft) Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology Guidance for Industry
21 The FDA not a definition when considering whether an FDA-regulated product involves the application of nanotechnology, FDA will ask: Whether (the product) has at least one dimension in the nanoscale range (approximately 1 nm to 100 nm); or exhibits properties or phenomena attributable to its dimension(s), even if..up to one micrometer. These considerations apply not only to new products, but also may apply when manufacturing changes alter the dimensions, properties, or effects of an FDA-regulated product or any of its components.
22 No specific exclusion for solubility No exclusion of organics, biomolecules Does include already authorized products when manufacturing is changed to affect function, and that change affects feature size in the submicron range.
23 FDA is not focusing on definitions of nanomaterial to create new product reviews, rather, they are focusing on when new manufacturing (nanotechnology, even if it is not called that) creates new properties and therefore a new product.
24 A Hint of What s to Come This guidance document does not establish any regulatory definitions. Rather, it is intended to help industry and others identify when they should consider potential implications for regulatory status, safety, effectiveness, or public health impact that may arise with the application of nanotechnology in FDA-regulated products.
25 First in a series of regulatory definitions? Dietary Supplements July 2011 Draft Guidance for Public Comment cuments/dietarysupplements/ucm htm#iii-scope
26 Dietary Supplements a change in the manufacturing process for a NDI* intended to produce particles in the 1 nm to 100 nm (approximate) nanoscale range may alter the chemical properties of the NDI. If so, the resulting ingredient with different chemical properties would likely not be covered under an existing notification for a related substance manufactured without using nanotechnology and, therefore, would likely require a NDI notification. Manufacturers planning a manufacturing change are encouraged to consult with FDA on any questions as to whether such a change would be viewed as having created a different NDI. *New Dietary Ingredient
27 Similar Guidance in Final Review for Food Additives and for Colors Drafts focus on when a change in manufacturing would change regulatory status such that a new notification or authorization would be reguired. Colors has more regarding data types to submit due to lesser pre-submission guidance currently out for colors.
28 Under Consideration at FDA Red book toxicity testing guidance Specific testing and characterization methods
29 FDA Recommends Regulatory Science Research for Nano FDA encourages promotion of, and participation in, regulatory science research and other efforts to increase scientific understanding, to facilitate assessment of data needs for regulated products. Such activities should, where appropriate, be coordinated with and leveraged against activities supported by other Federal agencies, the private sector, or other international regulatory counterparts.
30 FDA Research Categories for Nano Physico-Chemical Characterization improved methods and tools to detect and measure Nonclinical Modeling assays and models to assess safety and/or efficacy Risk Characterization to enhance the understanding of hazard identification, exposure science, and risk modeling. Risk Assessment development of generalized class-based approaches to risk assessment Risk Communication
31 What is needed to clarify engineered nano in food from food that is nano Agree to methods-based definitions for what is new nano after ph 2 transition in stomach Then agree to how to characterize persistent particles in gut, so they can be tested or related to pristine nano toxicity test data ILSI RF s NanoRelease project
32 Thank you
9/24/2012. Science Symposium FDA, Nanotechnology and Cosmetics Jay Ansell, PhD., DABT AGENDA
Science Symposium FDA, Nanotechnology and Cosmetics Jay Ansell, PhD., DABT October 3, 2012 Newark NJ AGENDA FDA Guidance and Council Response Current State of Science Conclusions Guidance for Industry
More informationNano Food: Regulation or the new GMO debate?
Nano Food: Regulation or the new GMO debate? Jaydee Hanson Center for Food Safety & International Center for Technology Assessment at webinar hosted by Collaborative on Health and the Environment April
More informationToxicological Assessment of (silver) Nanomaterials: Challenges and Pitfalls
Dr Helinor Johnston, Nano Safety Research Group Toxicological Assessment of (silver) Nanomaterials: Challenges and Pitfalls BfR Conference: Nanosilver Feb 2012 h.johnston@hw.ac.uk Nanotoxicology Nanotechnology
More informationReal Time Cell Electronic Sensing (RT-CES) for Nanotoxicity Evaluation
Real Time Cell Electronic Sensing (RT-CES) for Nanotoxicity Evaluation Reyes Sierra 1, Lila Otero 1, Scott Boitano 2 & Jim Field 1 1 Dept Chemical & Environmental Engineering 1 2 Dept Cell Physiology The
More informationScience & Research. Frequently Asked Questions. 1 of 6 7/8/ :52 PM
1 of 6 7/8/2010 11:52 PM Home > Science & Research > Science and Research Special Topics > Nanotechnology Science & Research Frequently Asked Questions 1. What is nanotechnology? While many definitions
More informationAssessing the Risks of Nanomaterials
Assessing the Risks of Nanomaterials J. Michael Davis, Ph.D. Senior Science Advisor National Center for Environmental Assessment U.S. Environmental Protection Agency Research Triangle Park, NC 27711 Davis.Jmichael@epa.gov
More informationEnvironmental Applications and Implications of Nanotechnology
Environmental Applications and Implications of Nanotechnology Association of State and Territorial Solid Waste Management Officials Annual Meeting Baltimore, MD October 23, 2008 Marti Otto Office of Superfund
More informationMoving toward Sustainability
Nanotechnology and the Environment: Moving toward Sustainability Barbara Karn, PhD Health and Environment Organization April 17, 2012 A bit of history Nanotechnology is enabled Nanotechnology is recognized
More informationRisk Management of Industrial Nanomaterials
Risk Management of Industrial Nanomaterials Eurachem Workshop MIKES, May 21 2013 Kai Savolainen Background Engineered nanomaterials (ENM) have unique properties that enable improving the quality of consumer
More informationReplacing Analytical Methods for Release and Stability Testing A Regulatory Perspective
Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh
More informationNanotoxicology. Some nanomaterial properties raise toxicity concerns. Small size. High surface area. Fibrous morphology
Nanotoxicology Some nanomaterial properties raise toxicity concerns Small size - small aerodynamic diameter deep lung penetration - high permeability in biological membranes - enhanced cellular uptake
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationNanotechnology in Food
ILSI SEA Region 6th Asian Conference on Food and Nutrition Safety (Nov 2012) http://www.ilsi.org/sea_region/pages/vieweventdetails.aspx?webid=4d540914-eeb6-40e4-89eb-0b73ba3d76c1&listid=478be3cb-581b-4ba2-a280-8e00ccb26f9c&itemid=66
More informationFood Irradiation: FDA s Perspective Teresa Croce, Ph.D.
Food Irradiation: FDA s Perspective Teresa Croce, Ph.D. Office of Food Additive Safety Center for Food Safety and Applied Nutrition US Food and Drug Administration March 23, 2016 Federal Food, Drug, &
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM March 2015 HPFBI CANADA (HEALTH CANADA) Notice, Re: Regulatory Decision Summaries and Submissions Under Review Who s affected? Manufacturers of prescription drugs (pharmaceuticals and
More informationOECD RECOMMENDATION ON THE SAFETY OF NANOMATERIALS
OECD RECOMMENDATION ON THE SAFETY OF NANOMATERIALS Workshop for the Asia-Pacific Region on Nanotechnology and Manufactured Nanomaterials: Safety Issues 10-11 September 2015, Bangkok, Thailand OECD Australia
More informationCritical Quality Attributes for Biotechnology Products: A Regulatory Perspective
Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationEnsuring Food and Feed Safety: US Food Law and FDA s Biotechnology Consultation Process
Ensuring Food and Feed Safety: US Food Law and FDA s Biotechnology Consultation Process Robert I. Merker FDA Center for Food Safety and Applied Nutrition Washington, DC Robert.Merker@fda.hhs.gov A key
More informationUsage of (eco)toxicological data for bridging data gaps between and grouping of nanoforms of the same substance. Elements to consider
Usage of (eco)toxicological data for bridging data gaps between and grouping of nanoforms of the same substance Elements to consider Nanomaterials based solutions have a lot to offer for a wide range of
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationCurrent Practices and Perceived Risks Related to Health, Safety and Environmental Stewardship in Nanomaterials Industries
Current Practices and Perceived Risks Related to Health, Safety and Environmental Stewardship in Nanomaterials Industries Cassandra Engeman, UCSB, Project Coordinator Barbara Herr Harthorn, UCSB, Principal
More informationMEDICINES CONTROL COUNCIL
PRE-REGISTRATION CONSULTATION MEETING MATERIAL CHECKLIST MEDICINES CONTROL COUNCIL PRE-REGISTRATION CONSULTATION MEETING MATERIAL The CHECKLIST is to be used for the preparation of a formal request to
More informationEffect of Zinc Oxide Nanoparticle on Strength of Cement Mortar
IJSTE - International Journal of Science Technology & Engineering Volume 3 Issue 05 November 2016 ISSN (online): 2349-784X Effect of Zinc Oxide Nanoparticle on Strength of Cement Mortar D. Nivethitha S.
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationDevelopment of National Nanotechnology Standards for Safe Consumer Products
Development of National Nanotechnology Standards for Safe Consumer Products Agus Haryono Research Center for Chemistry Indonesian Institute of Sciences (LIPI) International Conference on Nanotechnology
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationDrug Development and Incrementally Modified Drugs : Regulatory Perspective. American Association of Pharmaceutical Scientists October 27, 2015
Drug Development and Incrementally Modified Drugs : Regulatory Perspective American Association of Pharmaceutical Scientists October 27, 2015 Larissa Lapteva, M.D., M.H.S., Division of Therapeutic Performance
More informationToxicidad de los Nanomateriales para la salud. Introducción. Ejemplos. Situación actual y próximos pasos. Proyectos NANoREG y NanoReg 2.
Toxicidad de los Nanomateriales para la salud. Introducción. Ejemplos. Situación actual y próximos pasos. Proyectos NANoREG y NanoReg 2. Blanca Suarez Merino DPhil 1 Nano products VS Some Australians Prefer
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationEnvironmental Protection Agency-EPA. EPA Registration
Environmental Protection Agency-EPA EPA Registration Biochemical Product Chemistry http://www.epa.gov/fedrgstr/epa-pest/2007/october/day-26/p20828.htm htm Biological Pesticides (40 CFR 180.65) Unique modes
More informationQuestion / Answer Session. SEMI Webcast June 1, 2017
Question / Answer Session SEMI Webcast June 1, 2017 Q/A Session Participants U.S. EPA Jim Alwood (U.S. EPA) SEMI Staff and Members Sanjay Baliga (SEMI Global Headquarters) Rory McCarthy (Brewer Science)
More informationChinese Pharmaceutical Association
Chinese Pharmaceutical Association CPA[2012]No.22 2012 Chinese Pharmaceutical Conference The 1 st Round Conference Announcement Nanotechnology is a cutting edge technology with strategic importance in
More informationParadigm Shift in Comparability Assessment:
Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability
More informationGLOBAL FOOD, DRUGS, MEDICAL DEVICES AND COSMETICS NEWSLETTER
NEWSLETTER 3 rd Edition Fall 2014 Highlighting Issues and Developments across the Globe in the Food, Drugs, Medical Devices and Cosmetics Industries CONTENTS Legislative Updates (i) China Draft Amendments
More informationFDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010
FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010 FDA Nanotechnology Task Force Carlos Peña, PhD Office of the Commissioner & Subhas Malghan, PhD Center for Devices and
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More information参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft
参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.
More informationCreating an Effective Oversight System for Nanotechnology
Project on Emerging Nanotechnologies Creating an Effective Oversight System for Nanotechnology Mark Greenwood Project on Emerging Nanotechnologies is supported by The Pew Charitable Trusts Pen 7 March
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationSusan D. Ripple, MS, CIH, Fellow AIHA Industrial Hygiene Manager The Dow Chemical Company
Susan D. Ripple, MS, CIH, Fellow AIHA Industrial Hygiene Manager The Dow Chemical Company Risk Assessment Regulations 1 EU Directive & REACH 2 TSCA& Safe Chemicals Act 3 Impacts on Risk Assessment 4 Benefits
More informationTECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
1 2 3 17 January 2013 EMA/CHMP/13099/2013 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Joint MHLW/EMA reflection paper on the development of block copolymer micelle Agreed by Nanomedicines
More informationPhysico-chemical and toxicological studies of engineered nanoparticles emitted from printing equipment
Physico-chemical and toxicological studies of engineered nanoparticles emitted from printing equipment Sandra V. Pirela, M.S., Philip Demokritou, Ph.D. Doctoral Candidate Harvard School of Public Health
More informationCurrent Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues
Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Dr. René Thürmer BfArM - and dmedical ldevices AGAH Workshop on Liposomal Formulations Bonn / 21.
More informationFour Themes 1. Nanoscale materials have unique and useful properties, and uses are already growing quickly 2. Operators are now exploring nanotech in
Mixing Oil, Gas and Nano: Environmental Legal Implications of Using Nanotechnology in Oil and Gas Development Prof.Tracy Hester Emerging Technologies & Environmental Law Feb. 28, 2011 Four Themes 1. Nanoscale
More informationGuidance for Industry
Guidance for Industry Comparability Protocols - Protein Drug Products and Biological Products - Chemistry, Manufacturing, and Controls Information DRAFT GUIDANCE This guidance document is being distributed
More informationHighlights EPA publicly released a White Paper on Nanotechnology, 15 February 2007
UNITED STATES Highlights EPA publicly released a White Paper on Nanotechnology, 15 February 2007 NIOSH released Progress Toward Safe Nanotechnology in the Workplace, February 2007 NSET/NEHI held a public
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationMASTER FILE PROCEDURES
MASTER FILE PROCEDURES Natural Health Products Directorate August 2006 Version 1.0 Our mission is to help the people of Canada maintain and improve their health, while respecting individual choices and
More informationReflection Paper. The Role of Product-specific Monographs for Biotherapeutic Products in Pharmacopoeias
Reflection Paper 3 October 2014 The Role of Product-specific Monographs for Biotherapeutic Products in Pharmacopoeias This reflection paper describes a scientific and regulatory rationale for a new format
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4
More informationSpotlight on Animal Health Business Operations: A Legal Update Husch Blackwell LLP. March 5, 2015
Spotlight on Animal Health Business Operations: A Legal Update Husch Blackwell LLP March 5, 2015 Environmental Compliance, Planning and Management Systems I. Introduction A. Manufacturers and distributors,
More informationRegulation of Microbiota- Based Products
Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal
More informationNanomaterials in REACH
EUROPEAN COMMISSION ENVIRONMENT DIRECTORATE-GENERAL Water, Chemicals & Cohesion Chemicals ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Chemicals, Metals, Forest-based & Textile Industries REACH Brussels,
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationMicrofluidizer Processors:
30 Ossipee Road Newton, MA 02464 www.microfluidicscorp.com Microfluidizer Processors: Technology and Applications Presented by: Thomai Mimi Panagiotou, Ph.D. CTO Microfluidics at a Glance Headquartered
More informationInventory of Research on the Environmental, Health and Safety Implications of Nanotechnology
Inventory of Research on the Environmental, Health and Safety Implications of Nanotechnology Dr. Andrew Maynard, Chief Science Advisor, Project on Emerging Nanotechnologies, Woodrow Wilson International
More informationNonproprietary Naming of Biological Products
Nonproprietary Naming of Biological Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Guidelines on procedures and data requirements for changes to approved biotherapeutic products World Health Organization
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationNanotechnology and human health impact
Nanotechnology and human health impact A framework for strategic research? Andrew D. Maynard Chief Science Advisor Woodrow Wilson Center, Project on Emerging Nanotechnologies 1 Challenge! Nanotechnology
More informationBisphenol A Alternatives in Thermal Paper
Bisphenol A Alternatives in Thermal Paper Chapter 1 Introduction July 2012 DRAFT U.S. Environmental Protection Agency 1 1 Introduction As part of its effort to enhance the Agency s current chemicals management
More informationNanotechnology: Applications and Implications for the Environment. Alan G. Cummings CEO and Co-Founder Seldon Technologies
Nanotechnology: Applications and Implications for the Environment Alan G. Cummings CEO and Co-Founder Seldon Technologies Nanotechnology: Applications and Implications for the Environment Brenda Barry
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationof the indoor paint or varnish
rdic Ecolabelling 096/3 Appendix 1 Declaration from the manufacturer of the indoor paint or varnish To be used in conjunction with an application for a licence for the rdic Ecolabelling of indoor paint
More informationOptical Observation - Hyperspectral Characterization of Nano-scale Materials In-situ
Optical Observation - Hyperspectral Characterization of Nano-scale Materials In-situ Research at the nanoscale is more effective, when research teams can quickly and easily observe and characterize a wide
More informationACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY
ACVMS 9.1 Ministry of Agriculture and Forestry Post Office Box 2526 WELLINGTON, NEW ZEALAND ACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY This document may be altered at any
More informationThe Device Side of Combination Products
The Device Side of Combination Products Technical and Regulatory Challenges in Life Cycle Management Bob Laughner Associate Director, Combination Products 04 May 2016 What are combination products? Combination
More informationBiosimilars Scientific Challenges and Implications
Biosimilars Scientific Challenges and Implications Professor Paul Declerck Laboratory for Therapeutic and Diagnostic Antibodies paul.declerck@pharm.kuleuven.be Biological medicinal product A well-defined
More informationUnder this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at
DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993 Our STN: BL 125387/0 BLA APPROVAL November 18, 2011 Regeneron Pharmaceuticals, Inc. Attention: Laura Pologe, Ph.D. Associate Director, Regulatory
More informationWorkshop on Nanoscience and Catalysts March 2008, QAU, Islamabad Nanocomposites for Thermal management Applications
Fazal Ahmad Khalid Pro-Rector GIK Institute of Engineering Sciences and Technology Topi, NWFP, Pakistan (Khalid@giki.edu.pk) Workshop on Nanoscience and Catalysts 24-25 March 2008, QAU, Islamabad Nanocomposites
More informationJames J. Jones Deputy Assistant Administrator EPA Office of Chemical Safety and Pollution Prevention
James J. Jones Deputy Assistant Administrator EPA Office of Chemical Safety and Pollution Prevention EPA Organizational Structure Agency Wide Science and Risk Assessment Processes Office of Pesticide Programs
More informationRegulating the Impacts of Nanomaterials: Identifying Gaps in Characterizing Risk
Regulating the Impacts of Nanomaterials: Identifying Gaps in Characterizing Risk Tess Garvey, Kirti Richa, Dr. Gabrielle Gaustad and Dr. Callie Babbitt Sustainable Nanotechnology Conference November 5,
More informationGuidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center
More informationOrganisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development
Unclassified ENV/JM/MONO(2016)58 ENV/JM/MONO(2016)58 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 04-Nov-2016 English
More informationOpportunities and Impacts
Nanotechnology: Opportunities and Impacts of a Scientific Revolution National Conference of State Legislatures Nashville, Tennessee August 16, 2006 James B. Roberto Deputy Director for Science and Technology
More informationNanoHealth Enterprise Initiative Engineered Nanomaterials Research and Training
NanoHealth Enterprise Initiative Engineered Nanomaterials Research and Training Executive Summary The properties that emerge at the nanoscale size, surface-area-to-mass ratio, shape, crystal structure,
More informationAgilent TRS100 Raman. Quantitative Pharmaceutical Analysis System
Agilent TRS100 Raman Quantitative Pharmaceutical Analysis System Agilent TRS100 Raman Streamlined Quality Control Fast Test hundreds of intact tablets or capsules in minutes Simple Quantify active pharmaceutical
More informationUS EPA Perspectives on GHS SCHC Fall Meeting. Kaitlin Keller, Pesticide Re-evaluation Division Office of Pesticide Programs, USEPA September 27, 2017
1 US EPA Perspectives on GHS SCHC Fall Meeting Kaitlin Keller, Pesticide Re-evaluation Division Office of Pesticide Programs, USEPA September 27, 2017 2 Background: GHS GHS was adopted by the UN in 2003;
More informationThe challenges of potency assay development for cell-based medicinal products in Europe
Focus Advanced therapies 5 The challenges of potency assay development for cell-based medicinal products in Europe Authors Valerie Pimpaneau, Senior Director, Voisin Consulting Life Sciences; François
More informationTransparent zinc oxide
Transparent zinc oxide Umicore Umicore is a specialty materials group which employs some 13.000 people, has industrial operations on all continents and serves a global customer base. Its activities are
More informationAn Integrated Analytical Approach to Implement the European Definition of a Nanomaterial
An Integrated Analytical Approach to Implement the European Definition of a Nanomaterial Hans Marvin & Felice Simeone RIKILT Wageningen UR www.nanodefine.eu The European Materials Characterisation Council
More informationICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management
1 2 3 14 December 2017 EMA/CHMP/ICH/804273/2017 Committee for Medicinal Products for Human Use 4 5 6 7 ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle
More informationNanotechnologie in der Lebensmittelindustrie
Nanotechnologie in der Lebensmittelindustrie Peter Schurtenberger Department of Physics and Fribourg Center for Nanomaterials (FriMat) University of Fribourg 1700 Fribourg, Switzerland www.unifr.ch/physics/mm/
More informationDate: September 11, 2017 Reference No.: FDAA17008
Date: September 11, 2017 Reference No.: FDAA17008 VIA WEB Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBJECT: Draft Standardization
More informationWHAT DO WE MEAN BY NANOSCIENCE OR NANOTECHNOLOGY EDUCATION?
2nd US-Korea NanoForum, Los Angeles, USA, February 17-19, 2005 WHAT DO WE MEAN BY NANOSCIENCE OR NANOTECHNOLOGY EDUCATION? Donald R. Baer Pacific Northwest National Laboratory don.baer@pnl.gov Talk intended
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines
0 0 0 0 WHO/PAC for BTPs_DRAFT/ Oct 0 ENGLISH ONLY Guidelines on procedures and data requirements for changes to approved biotherapeutic products Proposed guidelines NOTE: This document has been prepared
More informationwas published. February 21, 2017
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationRe: Docket No. FDA-2014-D-1461: Rare Pediatric Disease Priority Review Vouchers
February 13, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2014-D-1461: Rare Pediatric Disease Priority Review
More informationCTA is a Washington, D.C.-based non-profit, bi- partisan organization committed to providing the public with full assessments and analyses of technolo
Nanotechnology: A Risky Future? George A. Kimbrell The International Center for Technology Assessment Harris Martin s Cutting Edge Toxic Tort Conference December 11, 2006 Scottsdale, AZ CTA is a Washington,
More informationPUBLIC CONSULTATION AT STEP 4 OF THE VICH PROCEDURE OVERVIEW OF COMMENTS RECEIVED
VICH/12/056 FINAL PUBLIC CONSULTATION AT STEP 4 OF THE VICH PROCEDURE OVERVIEW OF COMMENTS RECEIVED VICH draft Guideline 54 - Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food:
More informationFood applications of nanoscience and nanotechnologies
Food applications of nanoscience and nanotechnologies Sue O Hagan CIAA Science Group Science Leader Food Safety, Unilever Overview of the Presentation Presentation of CIAA and its members General remarks
More informationDECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE
DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity
More informationOverview of USP Activities and How to Get Involved
Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting
More informationNanoRelease Food Additive
NanoRelease Food Additive FoodDrinkEurope FIVE YEARS NANOTECHNOLOGY DIALOGUE Time to review Achievements and Omissions 19 October 2012 David Carlander ISSUE AT HAND NanoRelease Food Additive No widely
More information